Restless Legs: When to See a Doctor

Red Flags That Demand a Doctor Visit

RLS crosses from nuisance to medical concern when it steals your sleep consistently. The International Restless Legs Syndrome Study Group (IRLSSG) defines clinically significant RLS as symptoms occurring at least three times weekly for three months or longer [1]. If you hit that threshold, you need evaluation.

Specific warning signs that warrant prompt medical attention include daytime fatigue severe enough to impair driving or work performance, depressive symptoms emerging alongside the leg discomfort, and onset before age 40 with a family history (which suggests a genetic form requiring different management). RLS that starts suddenly after beginning a new medication (particularly antidepressants, antihistamines, or antipsychotics) also requires physician review, since drug-induced RLS resolves with medication adjustment rather than RLS-specific therapy [2].

The American Academy of Sleep Medicine (AASM) 2012 clinical practice guideline emphasizes that patients with RLS-related insomnia lasting more than one month should receive formal evaluation, as chronic sleep deprivation compounds cardiovascular and metabolic risk independently of the RLS itself [3]. A 2012 meta-analysis published in the European Journal of Epidemiology found that RLS was associated with a 40% increased risk of cardiovascular disease (RR 1.40 to 95% CI 1.19-1.64) [4].

What Actually Causes Restless Legs

The pathophysiology centers on two interacting systems: brain iron metabolism and dopaminergic signaling. These aren't separate problems. They feed each other.

Autopsy studies and MRI-based iron quantification have consistently shown reduced iron content in the substantia nigra of RLS patients compared to controls, even when serum iron levels appear normal [5]. Iron serves as a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. When brain iron drops, dopamine production becomes erratic, particularly in the evening hours when dopamine levels physiologically decline.

Primary (idiopathic) RLS has a strong genetic component. Genome-wide association studies have identified variants in MEIS1, BTBD9, and MAP2K5/SKOR1 loci that collectively increase risk by 50% or more [6]. If one parent has RLS, offspring carry a 3-to-6-fold increased risk.

Secondary RLS has identifiable triggers:

• Iron deficiency: the most common and most treatable cause. Serum ferritin below 75 mcg/L is the treatment threshold for RLS, not the general anemia cutoff of 12-15 mcg/L [7].
• Pregnancy: affects 25-30% of pregnant women, particularly in the third trimester, and typically resolves within four weeks postpartum.
• End-stage renal disease: prevalence reaches 25-50% in dialysis patients due to impaired iron utilization and uremic toxin accumulation [8].
• Peripheral neuropathy: diabetes, B12 deficiency, and alcohol-related neuropathy can all produce RLS-mimicking or RLS-triggering sensations.
• Medications: SSRIs, SNRIs, mirtazapine, diphenhydramine, and dopamine-blocking antiemetics (metoclopramide, prochlorperazine) all worsen or trigger RLS.

How Doctors Diagnose RLS

RLS remains a clinical diagnosis. No blood test or imaging study confirms it. The IRLSSG revised 2014 diagnostic criteria require all five of the following features [1]:

An urge to move the legs, usually accompanied by uncomfortable sensations. The urge begins or worsens during rest or inactivity. Movement partially or totally relieves the urge. Symptoms are worse in the evening or night. These features are not solely accounted for by another condition (leg cramps, positional discomfort, habitual foot tapping).

The fifth criterion matters most in clinical practice. Dr. Richard Allen, a neurologist at Johns Hopkins who co-authored the IRLSSG criteria, has stated: "The mimics of RLS are more common than RLS itself. Leg cramps, peripheral neuropathy, and akathisia all produce an urge to move, but the circadian pattern and relief with movement distinguish true RLS" [9].

Your physician should order serum ferritin, transferrin saturation, a complete metabolic panel (to screen for renal disease), hemoglobin A1c, and vitamin B12 levels. Polysomnography is not required for diagnosis but may be ordered if periodic limb movement disorder (PLMD) is suspected or if the diagnosis remains uncertain. Approximately 80-90% of RLS patients exhibit periodic limb movements during sleep (PLMS), defined as repetitive dorsiflexion episodes occurring at 20-to-40-second intervals [10].

Iron: The Treatment Most Doctors Skip

Correcting iron deficiency resolves or substantially improves RLS in a large proportion of patients, yet many clinicians fail to check ferritin or use the wrong threshold.

The IRLSSG consensus guideline recommends treating with oral or intravenous iron when serum ferritin is below 75 mcg/L or transferrin saturation is below 20%, regardless of whether the patient meets criteria for anemia [7]. A 2019 Cochrane review of iron therapy for RLS (12 trials, 496 participants) found that intravenous iron significantly reduced RLS symptom severity compared to placebo (mean difference on the IRLS rating scale: -8.0 points, 95% CI -11.8 to -4.2), while oral iron showed a smaller but still clinically meaningful benefit [11].

For oral supplementation, ferrous sulfate 325 mg taken with 100 mg vitamin C on an empty stomach every other day optimizes absorption based on hepcidin cycling data [12]. If ferritin remains below 75 mcg/L after 12 weeks of oral therapy, or if the patient cannot tolerate oral iron, intravenous ferric carboxymaltose (750 mg x 2 doses one week apart) or iron sucrose provides faster repletion.

The target: get ferritin above 100 mcg/L and reassess symptoms after 8-12 weeks. Many patients with secondary RLS require no additional pharmacotherapy once iron stores are replenished.

First-Line Drug Therapy: Alpha-2-Delta Ligands

The IRLSSG 2016 treatment algorithm and the AASM 2012 guideline both shifted first-line pharmacotherapy away from dopamine agonists toward alpha-2-delta calcium channel ligands [3][13]. This was not a minor adjustment. It reflected a decade of evidence showing that dopamine agonists, while effective short-term, carry unacceptable rates of augmentation with chronic use.

Gabapentin enacarbil (Horizant) 600 mg taken at 5 PM is the only alpha-2-delta ligand with FDA approval specifically for moderate-to-severe RLS. In the key 12-week trial (N=222), gabapentin enacarbil reduced IRLS scores by 13.2 points versus 8.8 for placebo (P<0.001) [14]. Side effects include somnolence (20%), dizziness (13%), and headache (12%).

Pregabalin 150-300 mg nightly demonstrated non-inferiority to pramipexole in a 52-week head-to-head trial (N=719) with significantly lower augmentation rates (2% vs. 8% at one year) [15]. The European Medicines Agency considers pregabalin a first-line option for RLS based on this evidence, though it lacks an FDA-specific RLS indication.

Gabapentin (standard formulation) 300-900 mg nightly is used off-label when insurance denies gabapentin enacarbil or pregabalin. Absorption is variable and dose-dependent, making it less predictable than the extended-release prodrug.

When Dopamine Agonists Still Make Sense

Dopamine agonists remain appropriate in specific situations: patients who cannot tolerate alpha-2-delta ligands, those with severe RLS requiring rapid symptom control as a bridge, and patients with comorbid RLS and Parkinson disease.

Pramipexole 0.125-0.5 mg and ropinirole 0.25-4 mg nightly both have FDA approval for RLS. Short-term efficacy is excellent. The problem is augmentation, a paradoxical worsening of RLS symptoms that develops in 40-70% of patients treated with dopamine agonists for more than five years [16]. Augmentation manifests as earlier onset of symptoms during the day, spread of symptoms to the arms or trunk, and increased intensity despite stable or increasing doses.

The IRLSSG recommends using the lowest effective dose, never exceeding pramipexole 0.5 mg or ropinirole 4 mg for RLS, and monitoring specifically for augmentation at each follow-up visit [13]. Dr. Diego Garcia-Borreguero, director of the Sleep Research Institute in Madrid and lead author of the IRLSSG treatment algorithm, has noted: "Augmentation is not an if but a when for most patients on long-term dopamine agonist therapy. The question is whether we can delay it long enough for the drug to remain clinically useful" [16].

If augmentation develops, the standard approach involves a slow 25% dose reduction every two weeks while cross-titrating to an alpha-2-delta ligand or adding low-dose opioid therapy for severe rebound symptoms.

Non-Pharmacologic Interventions That Have Evidence

Not everything requires a prescription. Several behavioral and physical interventions have randomized trial support, though effect sizes are generally smaller than pharmacotherapy.

Exercise: A 2016 randomized trial (N=28 hemodialysis patients with RLS) found that 16 weeks of moderate aerobic exercise three times weekly reduced IRLS scores by 46% compared to 2% in controls [17]. The timing matters: exercise completed more than four hours before bedtime helps, while vigorous evening exercise can acutely worsen symptoms.

Pneumatic compression devices: The FDA-cleared Relaxis pad (vibrotactile counterstimulation) reduced time to sleep onset by 11 minutes versus sham in a 35-night crossover trial [18]. Sequential pneumatic compression (similar to devices used for DVT prophylaxis) showed a 39% improvement in IRLS scores in a small randomized trial.

Sleep hygiene modifications specific to RLS: consistent sleep-wake schedule (RLS worsens with irregular schedules), cool bedroom temperature (heat exacerbates symptoms), avoidance of alcohol and caffeine after noon (both lower the sensory threshold for RLS symptoms), and mental alerting activities during symptomatic periods (crossword puzzles, video games) which paradoxically reduce the urge to move through cortical activation.

Magnesium: frequently recommended, poorly supported. A single small crossover trial (N=10) from 1998 suggested benefit, but no adequately powered study has replicated the finding [19]. It is reasonable to correct documented magnesium deficiency but not to recommend supplementation as RLS therapy.

RLS in Pregnancy: A Special Case

Between 25% and 30% of pregnant women develop RLS, predominantly during the third trimester [20]. The mechanism likely involves a combination of iron depletion (fetal demand), folate consumption, and hormonal shifts affecting dopaminergic tone.

Management during pregnancy is constrained by fetal safety concerns. Iron supplementation is first-line and often sufficient. Beyond iron, the evidence base thins considerably. Gabapentin carries a Category C rating and lacks large pregnancy safety studies. Dopamine agonists are Category C as well, with animal data showing skeletal abnormalities at high doses.

The reassuring data point: 97% of pregnancy-onset RLS resolves within four weeks of delivery [20]. For the 3% who develop persistent postpartum RLS, standard treatment algorithms apply, with attention to breastfeeding compatibility if applicable.

The Cardiovascular Connection

RLS is not merely a sleep annoyance. Large epidemiological studies have linked moderate-to-severe RLS with increased cardiovascular morbidity, independent of sleep duration.

A prospective analysis from the Nurses' Health Study (N=70,977; median follow-up 10 years) found that women with RLS had a 45% higher risk of incident coronary heart disease (HR 1.45 to 95% CI 1.10-1.91) after adjustment for age, BMI, smoking, physical activity, and other cardiovascular risk factors [21]. Whether RLS causes cardiovascular disease through sympathetic activation and chronic sleep fragmentation, or whether both conditions share a common upstream mechanism (iron dysregulation, endothelial dysfunction), remains an active area of investigation.

This association has practical implications for your doctor visit. If you have RLS plus hypertension, diabetes, or elevated inflammatory markers, the cardiovascular risk context strengthens the argument for aggressive RLS treatment rather than a watch-and-wait approach.

What to Expect at Your First Appointment

Prepare for your visit by tracking symptoms for at least two weeks. Document what time symptoms begin each evening, what relieves them, how long relief lasts, and how many hours of sleep you actually obtain. This log speeds diagnosis and helps your clinician distinguish RLS from mimics.

Expect blood work: ferritin, CBC, CMP, B12, folate, hemoglobin A1c, and thyroid panel at minimum. If ferritin returns below 75 mcg/L, your doctor should initiate iron repletion before considering any other therapy. If ferritin is adequate and symptoms meet IRLSSG criteria, an alpha-2-delta ligand will likely be offered first.

Follow-up at 4-6 weeks allows dose titration. Most patients achieve adequate control within 2-3 dose adjustments. For those who do not respond to first-line therapy, referral to a sleep medicine specialist is appropriate, as refractory RLS may require combination therapy or reassessment of the diagnosis.

The IRLS rating scale (a 10-item questionnaire, score range 0-40) is the standard outcome measure. A reduction of 6 or more points is considered clinically meaningful. Scores above 21 indicate severe RLS. Track your own score over time to objectively assess treatment response rather than relying on subjective impression alone.